000			03068nam a22003975i 4500
999			_c103463 _d103463 _x1
001			103463
003			DE-He213
005			20230221040153.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			140908s2015 si | s |||| 0|eng d
020			_a9789814585088
024	7		_a10.1007/978-981-4585-08-8 _2doi
040			_bspa _dES-MaUEC
050		4	_aQP531 _b2015 EB
100	1		_aKashyap, Amita. _eautor. _4aut _4http://id.loc.gov/vocabulary/relators/aut _0http://id.loc.gov/authorities/names/n2015180580 _1http://viaf.org/viaf/313491755/ _9101043
245	1	0	_aBioinformatics of Non Small Cell Lung Cancer and the Ras Proto-Oncogene _cby Amita Kashyap, D. Bujamma, Naresh Babu M.
264		1	_aSingapore _bSpringer International Publishing _c2015
300			_a1 recurso en línea (VII, 72 páginas 40 ilustraciones, 39 ilustraciones a color.)
336			_2rdacontent _aTexto (visual) _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
490	0		_aSpringerBriefs in Forensic and Medical Bioinformatics, _x2196-8845
490	0		_aEngineering (Springer-11647)
505	0		_aIntroduction -- Review of Literature -- Materials and Methods (Tools and Databases) -- Flowchart -- Conclusion.-References.
520	3		_aCancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 10-30% of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking studies. This brief involves extensive role of the RAS subfamily that includes a set of proteins, which cause an over expression of cancer-causing genes like M-ras and initiate tumour formation in lungs. SNP Studies and Structure based drug discovery will also be undertaken.
988			_aEBSPRINGER_2018
650		7	_9160956 _aQuímica bioinorgánica _2embne
700	1		_aBujamma, D. _eautor. _4aut _4http://id.loc.gov/vocabulary/relators/aut _0http://id.loc.gov/authorities/names/n2015180582 _1http://viaf.org/viaf/313491756/
700	1		_aBabu M, Naresh. _eautor. _4aut _4http://id.loc.gov/vocabulary/relators/aut _1http://viaf.org/viaf/313491757/
776	0	8	_iEdición impresa: _z9789814585071
776	0	8	_iEdición impresa: _z9789814585095
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-981-4585-08-8 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b03/2019 _dz _eIG _zSI